Latest Ratios: P/E Ratio -0.3x · EV/EBITDA N/A · ROE -256.4%. (1996–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $5M | $8M | $13M | $7M | $11M | $3M | $26M | $43M | $29M | $24M | $9M |
| Enterprise Value | $-3234829 | $315630 | $8M | $3M | $6M | $-9582147 | $15M | $47M | $25M | $12M | $9M |
| P/E Ratio → | -0.26 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | 22.18 | 6.74 | 52.19 | 85.87 | 57.02 | 47.01 | 17.91 |
| P/B Ratio | 0.54 | 1.15 | 2.96 | 0.53 | 0.38 | 0.06 | 1.40 | 2.95 | 1.37 | 0.88 | 1.33 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | 11.73 | -19.16 | 30.25 | 94.79 | 49.15 | 24.13 | 17.78 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating Margin | — | — | — | — | -4984.3% | -4201.4% | -3697.3% | -4113.1% | -4213.0% | -3693.7% | -4130.0% |
| Net Profit Margin | — | — | — | — | -7179.6% | -4153.9% | -4296.7% | -3370.3% | -2376.7% | -4080.4% | -4410.7% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -256.4% | -256.4% | -211.2% | -91.4% | -84.3% | -55.8% | -129.5% | -95.2% | -50.0% | -122.1% | -162.7% |
| ROA | -131.7% | -131.7% | -117.7% | -59.2% | -60.8% | -37.2% | -56.7% | -39.6% | -25.2% | -52.1% | -55.2% |
| ROIC | — | — | -330.5% | -94.8% | -55.8% | -62.4% | -104.0% | -85.8% | -98.2% | -126.4% | -128.0% |
| ROCE | -232.6% | -232.6% | -196.7% | -86.8% | -49.2% | -42.8% | -60.5% | -57.8% | -51.3% | -57.9% | -66.5% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.14 | 0.14 | 0.27 | 0.12 | 0.21 | 0.12 | 0.33 | 0.78 | 0.45 | — | 0.38 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -1.10 | -1.12 | -0.31 | -0.18 | -0.23 | -0.59 | 0.31 | -0.19 | -0.43 | -0.01 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | -104.52 | -6.45 | -37.87 | -17.05 | -12.40 | -30.32 | -221.35 | -29.50 |
Net cash position: cash ($9M) exceeds total debt ($1M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.32 | 2.32 | 1.67 | 2.47 | 3.66 | 7.67 | 2.79 | 2.06 | 4.61 | 3.92 | 0.54 |
| Quick Ratio | 2.32 | 2.32 | 1.67 | 2.47 | 3.66 | 7.67 | 2.79 | 2.06 | 4.61 | 3.92 | 0.54 |
| Cash Ratio | 1.90 | 1.90 | 1.23 | 2.12 | 3.26 | 7.30 | 2.54 | 1.88 | 4.52 | 3.90 | 0.51 |
| Asset Turnover | — | — | — | — | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.02 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | 94.12 | 79.46 | — | 15.60 | 49.87 | 39.74 | 2.93 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | 0.3% | 0.1% | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.3% | 0.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $2M | $882292 | $693474 | $547627 | $27737 | $163357 | $111590 | $89868 | $38983 | $9476 |
Binary clinical trial failure
According to recent market data, Imunon trades at a price-to-book ratio of 0.54, which, based on reported figures, suggests the market is pricing the company at a significant discount to its tangible assets due to the high probability of future equity dilution and clinical failure.
The current P/B multiple indicates that investors are assigning little to no value to the company's intangible pipeline assets, viewing the firm primarily through the lens of its liquidation risk. This valuation gap relative to peers suggests that the market remains skeptical of the TheraPlas platform's ability to generate commercial value before the company exhausts its remaining capital.
As reported in financial statements, Imunon's return on equity has consistently remained in deep negative territory, reaching -81.5% in 2026Q1, which highlights the company's inability to generate any meaningful return on invested capital while it remains in a pre-revenue, high-burn clinical development phase.
The persistent decay in ROE is a direct consequence of the company's reliance on external financing to fund R&D, which continuously expands the share count while failing to produce commercialized assets. This trend suggests that shareholders are experiencing significant value destruction, as capital is consumed by operational overhead rather than being compounded through successful clinical milestones.
Based on the company's reported figures, the current ratio has fluctuated significantly, settling at 1.59 in 2026Q1, which, when viewed alongside the rapid depletion of cash reserves, suggests that the firm's ability to cover short-term obligations is becoming increasingly dependent on immediate, dilutive capital raises.
While a current ratio above 1.0 might appear adequate in isolation, the lack of recurring revenue means that this liquidity is essentially a 'ticking clock' rather than a sustainable buffer. Investors should monitor the quick ratio closely, as any further decline in cash-on-hand relative to accrued clinical liabilities could signal an imminent liquidity crisis.
Analysts frequently misapply the price-to-earnings ratio to Imunon, which, as shown by the TTM P/E of -0.26, obscures the company's true financial health by focusing on accounting losses rather than the critical 'cash runway to milestone' metric required for clinical-stage biotechnology firms.
Using P/E or EV/EBITDA for a pre-revenue entity is fundamentally flawed because these metrics assume a steady-state business model that does not exist here. Instead, analysts should prioritize a burn-rate analysis adjusted for upcoming clinical trial milestones, as this provides a more accurate assessment of the company's survival probability and potential for future dilution.
Includes 30+ ratios · 30 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying IMNN stock.
Imunon, Inc.'s current P/E ratio is -0.3x. This places it at the 50th percentile of its historical range.
Imunon, Inc.'s return on equity (ROE) is -256.4%. The historical average is -118.4%.
Based on historical data, Imunon, Inc. is trading at a P/E of -0.3x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Imunon, Inc.'s current dividend yield is 0.27%.